Prostate cancer (PrCa) is a highly heterogeneous disease and its prognosis, diagnosis and management are still controversial. ERG rearrangements and PTEN loss are frequent and concomitant events in a subset of PrCa. The aim of this thesis is to analyze the potential use of TMPRSS2-ERG and SLC45A3-ERG rearrangements, along with ERG and PTEN expression in the stratification and prognosis of PrCa patients. TMPRSS2-ERG and ERG mRNA overexpression levels are related to a more aggressive phenotype and could be useful PrCa progression markers. Single TMPRSS2-ERG is associated with low grade PrCa and subsequent development of SLC45A3-ERG results in higher ERG expression. The triple hit (TMPRSS2-ERG, SLC45A3-ERG and PTEN loss) is not found in low ...
OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most com...
Background Phosphatase and tensin homolog (PTEN) gene aberration and trans membrane protease, serine...
The second most prevalent cancer among men with a 5-year survival rate of 30%, prostate cancer is a ...
Prostate cancer (PrCa) is a highly heterogeneous disease and its prognosis, diagnosis and management...
TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss a...
Prostate cancer (PC) is one of the most common neoplasms in men around the world. Current tools avai...
Recurrent gene fusions between the genes TMPRSS2 and ERG have been described in prostate cancer (PCa...
Objectives: Phosphate and tensin homolog gene (PTEN) acts as a regulator of P13-K-Akt molecular path...
none23siBACKGROUND: Whether the genomic rearrangement transmembrane protease, serine 2 (TMPRSS2):...
in prostate cancer (PC) and evaluate their prognostic significance. Despite conflicting published r...
The majority of prostate cancer harbors recurrent gene fusions involving ETS transcription factors, ...
TMPRSS2–ERG is the most frequent type of genomic rearrangement present in prostate tumors, in which ...
Background: TMPRSS2:ERG gene aberration may be a novel marker that improves risk stratification of p...
We have previously demonstrated a significant correlative relationship between PTEN deletion and ERG...
T1a prostate cancers (cancer found incidentally in transurethral resection, <5% of the tissue) are i...
OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most com...
Background Phosphatase and tensin homolog (PTEN) gene aberration and trans membrane protease, serine...
The second most prevalent cancer among men with a 5-year survival rate of 30%, prostate cancer is a ...
Prostate cancer (PrCa) is a highly heterogeneous disease and its prognosis, diagnosis and management...
TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss a...
Prostate cancer (PC) is one of the most common neoplasms in men around the world. Current tools avai...
Recurrent gene fusions between the genes TMPRSS2 and ERG have been described in prostate cancer (PCa...
Objectives: Phosphate and tensin homolog gene (PTEN) acts as a regulator of P13-K-Akt molecular path...
none23siBACKGROUND: Whether the genomic rearrangement transmembrane protease, serine 2 (TMPRSS2):...
in prostate cancer (PC) and evaluate their prognostic significance. Despite conflicting published r...
The majority of prostate cancer harbors recurrent gene fusions involving ETS transcription factors, ...
TMPRSS2–ERG is the most frequent type of genomic rearrangement present in prostate tumors, in which ...
Background: TMPRSS2:ERG gene aberration may be a novel marker that improves risk stratification of p...
We have previously demonstrated a significant correlative relationship between PTEN deletion and ERG...
T1a prostate cancers (cancer found incidentally in transurethral resection, <5% of the tissue) are i...
OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most com...
Background Phosphatase and tensin homolog (PTEN) gene aberration and trans membrane protease, serine...
The second most prevalent cancer among men with a 5-year survival rate of 30%, prostate cancer is a ...